

2018

Technical Report on
**critical concentrations
for drug susceptibility testing
of medicines used in the
treatment of drug-resistant
tuberculosis**



World Health
Organization

FIND 

Because diagnosis matters

WHO collaborating centre for the evaluation
of new diagnostic technologies

Technical Report on
**critical concentrations
for drug susceptibility testing
of medicines used in the
treatment of drug-resistant
tuberculosis**

© World Health Organization 2018

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organisation, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”.

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. Technical Report on critical concentrations for drug susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis. Geneva: World Health Organization; 2018 (WHO/CDS/TB/2018.5). Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Printed in Switzerland

WHO/CDS/TB/2018.5

Contents

Acknowledgements..... xiv

Members of the WHO Technical Expert Consultation Group..... xiv

Technical resource persons xiv

Additional literature reviewers xiv

Major data contributors xiv

Acknowledgement of financial support xv

Declaration and management of conflict of interest xv

Abbreviations xvii

Glossary of terms xix

Executive summary xxi

1. Introduction..... 3

 1.0 Background 3

 1.1 Scope of the Technical Expert Consultation Meeting 3

 1.2 Systematic review 4

 1.2.1 Search methodology..... 4

 1.2.2 Inclusion criteria 5

 1.2.3 Studies identified through the systematic review 5

 1.3 Data presentation 6

 1.3.1 Format of this report 6

 1.3.2 Format of MIC tables 6

2. Second-line injectable agents..... 8

 2.0 SLI MIC data stratification and current breakpoints..... 8

 2.A.1 KAN MIC data on LJ 8

 2.A.1.1 KAN MICs for pWT isolates on LJ..... 8

 2.A.1.2 KAN MICs for mutated isolates on LJ 9

 2.A.1.3 Conclusion for KAN CC for LJ 9

 2.A.2 KAN MIC data on 7H10 9

 2.A.2.1 KAN MICs for pWT isolates on 7H10 9

 2.A.2.2 KAN MICs for mutated isolates on 7H10. 11

 2.A.2.3 Conclusion for KAN CC for 7H10 14

 2.A.3 KAN MIC data on 7H11 14

 2.A.3.1 KAN MICs for pWT isolates on 7H11 14

| | |
|---|----|
| 2.A.3.2 KAN MICs for mutated isolates on 7H11 | 14 |
| 2.A.3.3 Conclusion for KAN CC for 7H11 | 14 |
| 2.A.4 KAN MIC data in MGIT..... | 14 |
| 2.A.4.1 KAN MICs for pWT isolates in MGIT | 14 |
| 2.A.4.2 KAN MICs for mutated isolates in MGIT..... | 16 |
| 2.A.4.3 Conclusion for KAN CC in MGIT..... | 17 |
| 2.A.5 References for KAN MIC studies | 17 |
| 2.B.1 AMK MIC data on LJ..... | 19 |
| 2.B.1.1 AMK MICs for pWT isolates on LJ | 19 |
| 2.B.1.2 AMK MICs for mutated isolates on LJ..... | 19 |
| 2.B.1.3 Conclusion for AMK CC on LJ..... | 20 |
| 2.B.2 AMK MIC data on 7H10..... | 20 |
| 2.B.2.1 AMK MICs for pWT isolates on 7H10 | 20 |
| 2.B.2.2 AMK MICs for mutated isolates on 7H10..... | 20 |
| 2.B.2.3 Conclusion for AMK CC on 7H10..... | 24 |
| 2.B.3 AMK MIC data on 7H11 | 24 |
| 2.B.3.1 AMK MICs for pWT isolates on 7H11 | 24 |
| 2.B.3.2 AMK MICs for mutated isolates on 7H11 | 25 |
| 2.B.3.3 Conclusion for AMK CC on 7H11 | 25 |
| 2.B.4 AMK MIC data in MGIT | 25 |
| 2.B.4.1 AMK MICs for pWT isolates in MGIT..... | 25 |
| 2.B.4.2 AMK MICs for mutated isolates in MGIT | 25 |
| 2.B.5 References for AMK MIC studies..... | 28 |
| 2.C.1 CAP MIC data on LJ..... | 30 |
| 2.C.1.1 CAP MICs for pWT isolates on LJ | 30 |
| 2.C.1.2 CAP MICs for mutated isolates on LJ..... | 30 |
| 2.C.1.3 Conclusion for CAP CC on LJ | 31 |
| 2.C.2 CAP MIC data on 7H10 | 31 |
| 2.C.2.1 CAP MICs for pWT isolates on 7H10..... | 31 |
| 2.C.2.2 CAP MICs for mutated isolates on 7H10 | 31 |
| 2.C.2.3 Conclusion for CAP CC on 7H10 | 35 |
| 2.C.3 CAP MIC data on 7H11 | 36 |
| 2.C.3.1 CAP MICs for pWT isolates on 7H11..... | 36 |
| 2.C.3.2 CAP MICs for mutated isolates on 7H11 | 36 |
| 2.C.3.3 Conclusion for CAP CC on 7H11 | 36 |
| 2.C.4 CAP MIC data in MGIT..... | 36 |
| 2.C.4.1 CAP MICs for pWT isolates in MGIT | 36 |
| 2.C.4.2 CAP MICs for mutated isolates in MGIT..... | 36 |
| 2.C.5 References for CAP MIC studies..... | 39 |

3. Clofazimine and bedaquiline 42

 3.0 CFZ and BDQ MIC data stratification and current breakpoints 42

 3.A.1 CFZ MIC data on LJ 42

 3.A.1.1 CFZ MICs for pWT isolates on LJ 42

 3.A.1.2 CFZ MICs for mutated isolates on LJ 42

 3.A.1.3 Conclusion for CFZ CC for LJ 42

 3.A.2 CFZ MIC data on 7H10 42

 3.A.2.1 CFZ MICs for pWT isolates on 7H10 42

 3.A.2.2 CFZ MICs for mutated isolates on 7H10 42

 3.A.2.3 Conclusion for CFZ CC for 7H10 42

 3.A.3 CFZ MIC data on 7H11 43

 3.A.3.1 CFZ MICs for pWT isolates on 7H11 43

 3.A.3.2 CFZ MICs for mutated isolates on 7H11 43

 3.A.3.3 Conclusion for CFZ CC for 7H11 43

 3.A.4 CFZ MIC data in MGIT 43

 3.A.4.1 CFZ MICs for pWT isolates in MGIT 43

 3.A.4.2 CFZ MICs for mutated isolates in MGIT 44

 3.A.4.3 Conclusion for CFZ CC for MGIT 44

 3.A.5 References for CFZ MIC studies 44

 3.B.1 BDQ MIC data on LJ 45

 3.B.1.1 BDQ MICs for pWT isolates on LJ 45

 3.B.1.2 BDQ MICs for mutated isolates on LJ 45

 3.B.1.3 Conclusion for BDQ CC for LJ 45

 3.B.2 BDQ MIC data on 7H10 45

 3.B.2.1 BDQ MICs for pWT isolates on 7H10 45

 3.B.2.2 BDQ MICs for mutated isolates on 7H10 46

 3.B.2.3 Conclusion for BDQ CC for 7H10 46

 3.B.3 BDQ MIC data on 7H11 46

 3.B.3.1 BDQ MICs for pWT isolates on 7H11 46

 3.B.3.2 BDQ MICs for mutated isolates on 7H11 47

 3.B.3.3 Conclusion for BDQ CC for 7H11 48

 3.B.4 BDQ MIC data in MGIT 49

 3.B.4.1 BDQ MICs for pWT isolates in MGIT 49

 3.B.4.2 BDQ MICs for mutated isolates in MGIT 49

 3.B.4.3 Conclusion for BDQ CC for MGIT 50

 3.B.5 References for BDQ MIC studies 50

4. Cycloserine and terizidone..... 52

- 4.0 DCS and TRD MIC data stratification and current breakpoints 52
- 4.1 DCS MIC data on LJ 52
 - 4.1.1 DCS MICs for pWT isolates on LJ 52
 - 4.1.2 DCS MICs for mutated isolates on LJ 52
 - 4.1.3 Conclusion for DCS CC for LJ 53
- 4.2 DCS MIC data on 7H10 53
 - 4.2.1 DCS MICs for pWT isolates on 7H10 53
 - 4.2.2 DCS MICs for mutated isolates on 7H10..... 53
 - 4.2.3 Conclusion for DCS CC for 7H10..... 53
- 4.3 DCS MIC data on 7H11 53
 - 4.3.1 DCS MICs for pWT isolates on 7H11 53
 - 4.3.2 DCS MICs for mutated isolates on 7H11..... 53
 - 4.3.3 Conclusion for DCS CC for 7H11..... 53
- 4.4 DCS MIC data in MGIT 53
 - 4.4.1 DCS MICs for pWT isolates in MGIT 53
 - 4.4.2 DCS MICs for mutated isolates in MGIT 54
 - 4.4.3 Conclusion for DCS CC for MGIT 54
- 4.5 References for DCS MIC studies 54

5. Linezolid 55

- 5.0 LZD MIC data stratification and current breakpoints 55
- 5.1 LZD MIC data on LJ 55
 - 5.1.1 LZD MICs for pWT isolates on LJ..... 55
 - 5.1.2 LZD MICs for mutated isolates on LJ 55
 - 5.1.3 Conclusion for LZD CC for LJ 55
- 5.2 LZD MIC data on 7H10 55

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_25957

